<?xml version="1.0" encoding="UTF-8"?>
<p>A different study used a delNS1-H5N1 as a live attenuated vaccine virus. After an intranasal monovalent dose, results revealed its safety and tolerability. Moreover, 75% of the participants displayed seroconversion after one immunization and IgA serum levels were increased after a second immunization [
 <xref rid="B125-ijms-21-01511" ref-type="bibr">125</xref>].
</p>
